NEW YORK, Jan. 7—IBM and Pharmacopeia subsidiary Accelrys have formed a wide-ranging drug discovery hardware and software technology and marketing alliance, the two firms said Monday.
The partnership, slated to last four years, will pair Accelrys' drug discovery software with IBM's server technology.
As part of the agreement, IBM also becomes Accelrys' preferred technology partner for life sciences, and its eServer systems will be the company's standard server. The software firm will use the IBM Regatta p690 system, the xSeries systems for Linux and Windows NT and the eServer Cluster 1300 system for Linux.
The two companies will jointly market drug discovery computer technology, including Accelrys' planned Discovery Studio platform, intended to integrate the entire process of drug discovery and development. IBM's DiscoveryLink data integration technology will be part of this new platform.
Accelrys will also enable its drug discovery applications to run optimally on eServer systems.
Accelrys also becomes a "premier partner" in IBM's "PartnerWorld for Developers Program," giving it top-drawer status as an IBM partner and access to the computer giant's sales, education, training and technical support programs.
The alliance is "one of the most significant and influential relationships for IBM in life sciences," said IBM Life Sciences general manager Caroline Kovac in a statement.
Accelrys was formed from Pharmacopeia's software subsidiaries last April. It is based in San Diego and Cambridge, UK.